FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1596989666> ?p ?o ?g. }

• W1596989666 abstract "Purpose Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is primarily treated with trastuzumab and other HER2-targeted therapies. However, approximately 30% of HER2-positive tumors exhibit de novo resistance, whereas 40% acquire resistance to these therapies. The mechanisms underlying drug resistance are unclear, and a better understanding of acquired resistance to HER2-targeted therapy is essential for the development of more effective therapeutics. Methods We enrolled 11 patients with HER2-positive breast cancer, all of whom had been treated with trastuzumab for one year and developed lung metastasis in the follow-up. We conducted exome sequencing of the primary and paired metastatic tumors from four patients. We identified somatic mutations in HER2 (K753E and L755S) affecting the kinase domain only in the metastatic lesions of two cases. Sanger sequencing was performed to analyze all exons of the HER2 gene in the paired primary and metastatic tumors of the remaining seven cases. Furthermore, we enrolled 48 patients with HER2-positive disease who underwent trastuzumab-based neoadjuvant therapy. We performed Sanger sequencing of the HER2 gene in paired tumor DNA before and after neoadjuvant therapy. To determine the phenotype of these mutations, we functionally characterized the HER2 mutations using protein structure analysis, in vitro kinase assays, cell culture, and xenograft experiments. Results We identified somatic mutations in HER2 affecting the kinase domain in four of 11 metastatic tumors (one case with K753E and three cases with L755S). None of the primary tumors harbored HER2 mutations. Furthermore, Sanger sequencing in the neoadjuvant setting revealed two of 48 cases harboring HER2 mutations (K753E and L755S) in the post-treatment samples, none of whom had any HER2 mutation in the paired pre-treatment tumor. Protein structure visualization hinted that the HER2 L753 and L755 side chains were in close proximity to the binding site for small-molecule inhibitors, indicating mutations at this residue might produce drug resistance. In vitro kinase assays revealed that HER2 K753E had greater tyrosine kinase-specific activity than wild-type. HER2 autophosphorylation, phosphorylation of HER2’s dimerization partners (EGFR or HER3) and downstream signaling proteins were significantly upregulated in MCF10A and MCF7 cells overexpressing HER2 K753E or L755S. Trastuzumab or lapatinib treatment did not decrease the number of colonies formed in MCF10A cells transduced with K753E or L755S. MCF7 cells bearing K753E or L755S mutant could reverse the inhibition of lapatinib in xenografts. The MCF10A-HER2 K753E and L755S cells were resistant to trastuzumab (IC 50 >1000μg/mL) and lapatinib (IC 50 >10μmol/L) but could be readily inhibited by neratinib (IC 50 of 15 nmol/L), an irreversible kinase inhibitor of HER2. Conclusion These data implicate that mutations in HER2 kinase domain are a key mechanism in resistance to HER2-targeted therapy. The selection of functional HER2 mutations might act as potential drivers of trastuzumab resistance during the progression of HER2-positive disease. Furthermore, more potent HER2 inhibitors such as neratinib might be of therapeutic benefit for trastuzumab-resistant breast cancer. Citation Format: Yizhou Jiang, Ke-Da Yu, Wen-Jia Zuo, Yu-Jie Wang, Zhi-Ming Shao. Exome sequencing identified emergence of HER2 kinase domain mutations in trastuzumab-resistant breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-04-02." @default.
• W1596989666 created "2016-06-24" @default.
• W1596989666 creator A5013085664 @default.
• W1596989666 creator A5032873998 @default.
• W1596989666 creator A5034686488 @default.
• W1596989666 creator A5062146153 @default.
• W1596989666 date "2015-04-30" @default.
• W1596989666 modified "2023-09-27" @default.
• W1596989666 title "Abstract P1-04-02: Exome sequencing identified emergence ofHER2kinase domain mutations in trastuzumab-resistant breast cancer" @default.
• W1596989666 doi "https://doi.org/10.1158/1538-7445.sabcs14-p1-04-02" @default.
• W1596989666 hasPublicationYear "2015" @default.
• W1596989666 type Work @default.
• W1596989666 sameAs 1596989666 @default.
• W1596989666 citedByCount "0" @default.
• W1596989666 crossrefType "proceedings-article" @default.
• W1596989666 hasAuthorship W1596989666A5013085664 @default.
• W1596989666 hasAuthorship W1596989666A5032873998 @default.
• W1596989666 hasAuthorship W1596989666A5034686488 @default.
• W1596989666 hasAuthorship W1596989666A5062146153 @default.
• W1596989666 hasConcept C104317684 @default.
• W1596989666 hasConcept C10590036 @default.
• W1596989666 hasConcept C121608353 @default.
• W1596989666 hasConcept C126322002 @default.
• W1596989666 hasConcept C143998085 @default.
• W1596989666 hasConcept C16671776 @default.
• W1596989666 hasConcept C2775930923 @default.
• W1596989666 hasConcept C2777329042 @default.
• W1596989666 hasConcept C2779786085 @default.
• W1596989666 hasConcept C2781164504 @default.
• W1596989666 hasConcept C2781230642 @default.
• W1596989666 hasConcept C501734568 @default.
• W1596989666 hasConcept C502942594 @default.
• W1596989666 hasConcept C530470458 @default.
• W1596989666 hasConcept C54355233 @default.
• W1596989666 hasConcept C71924100 @default.
• W1596989666 hasConcept C76818968 @default.
• W1596989666 hasConcept C86803240 @default.
• W1596989666 hasConceptScore W1596989666C104317684 @default.
• W1596989666 hasConceptScore W1596989666C10590036 @default.
• W1596989666 hasConceptScore W1596989666C121608353 @default.
• W1596989666 hasConceptScore W1596989666C126322002 @default.
• W1596989666 hasConceptScore W1596989666C143998085 @default.
• W1596989666 hasConceptScore W1596989666C16671776 @default.
• W1596989666 hasConceptScore W1596989666C2775930923 @default.
• W1596989666 hasConceptScore W1596989666C2777329042 @default.
• W1596989666 hasConceptScore W1596989666C2779786085 @default.
• W1596989666 hasConceptScore W1596989666C2781164504 @default.
• W1596989666 hasConceptScore W1596989666C2781230642 @default.
• W1596989666 hasConceptScore W1596989666C501734568 @default.
• W1596989666 hasConceptScore W1596989666C502942594 @default.
• W1596989666 hasConceptScore W1596989666C530470458 @default.
• W1596989666 hasConceptScore W1596989666C54355233 @default.
• W1596989666 hasConceptScore W1596989666C71924100 @default.
• W1596989666 hasConceptScore W1596989666C76818968 @default.
• W1596989666 hasConceptScore W1596989666C86803240 @default.
• W1596989666 hasLocation W15969896661 @default.
• W1596989666 hasOpenAccess W1596989666 @default.
• W1596989666 hasPrimaryLocation W15969896661 @default.
• W1596989666 hasRelatedWork W1541593398 @default.
• W1596989666 hasRelatedWork W1567668080 @default.
• W1596989666 hasRelatedWork W1754797577 @default.
• W1596989666 hasRelatedWork W2106301124 @default.
• W1596989666 hasRelatedWork W2120921373 @default.
• W1596989666 hasRelatedWork W2160828629 @default.
• W1596989666 hasRelatedWork W2334023120 @default.
• W1596989666 hasRelatedWork W2492858695 @default.
• W1596989666 hasRelatedWork W2529854314 @default.
• W1596989666 hasRelatedWork W2592058755 @default.
• W1596989666 hasRelatedWork W2613784923 @default.
• W1596989666 hasRelatedWork W2785383873 @default.
• W1596989666 hasRelatedWork W2895955393 @default.
• W1596989666 hasRelatedWork W2930274452 @default.
• W1596989666 hasRelatedWork W2943938066 @default.
• W1596989666 hasRelatedWork W2955475115 @default.
• W1596989666 hasRelatedWork W3081550180 @default.
• W1596989666 hasRelatedWork W3127974996 @default.
• W1596989666 hasRelatedWork W3175858454 @default.
• W1596989666 hasRelatedWork W73935639 @default.
• W1596989666 isParatext "false" @default.
• W1596989666 isRetracted "false" @default.
• W1596989666 magId "1596989666" @default.
• W1596989666 workType "article" @default.